Type 2 Diabetes Clinical Trials Enrolling in 2025

Why 2025 Is a Landmark Year for Type 2 Diabetes Research

The pace of Type 2 diabetes research has accelerated dramatically. In 2025, dozens of significant clinical trials are actively enrolling patients — testing everything from once-weekly insulin injections to combination pills that could replace multiple medications. For the estimated 38 million Americans living with Type 2 diabetes, these trials represent real opportunities to access tomorrow's treatments today, while contributing to science that will help millions of future patients.

This article covers the most significant active trials, what they're testing, and how patients can find and apply for them.

Next-Generation GLP-1 and Dual-Agonist Trials

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) revolutionized Type 2 diabetes treatment. In 2025, researchers are pushing further with dual and triple-agonist compounds that hit multiple metabolic targets simultaneously.

Eli Lilly's tirzepatide (Mounjaro), already approved for Type 2 diabetes, continues to generate trial data. The SURMOUNT-5 trial — comparing tirzepatide directly against semaglutide for weight loss in people with obesity and Type 2 diabetes — reported results in early 2025, showing tirzepatide achieved approximately 20% greater weight reduction. Lilly is now advancing retatrutide, a GIP/GLP-1/glucagon triple agonist, through Phase 3 trials with active enrollment in 2025 for patients with Type 2 diabetes and obesity.

Novo Nordisk is enrolling participants in the FLOW extension studies and advancing CagriSema — a combination of cagrilintide and semaglutide — through Phase 3 trials targeting patients with inadequately controlled Type 2 diabetes and high cardiovascular risk.

Oral Insulin: The Holy Grail Finally Within Reach?

For decades, an effective oral insulin has been the most sought-after goal in diabetes pharmacology. In 2025, several companies are in serious late-stage development.

Novo Nordisk's OI362GT oral insulin program is advancing, with the company conducting Phase 2 studies examining bioavailability improvements. Meanwhile, Oramed Pharmaceuticals completed Phase 3 data for its oral insulin capsule ORMD-0801, though results showed modest HbA1c reductions, and the company is analyzing subgroup data to identify which patients benefit most. Enrollment for follow-up studies continues in 2025.

These trials represent genuine scientific progress, though experts caution that oral insulin faces fundamental absorption challenges that no company has fully solved at scale yet.

Cardiovascular and Kidney Protection Trials

Some of the most important 2025 trials focus not on blood sugar itself, but on protecting the heart and kidneys — the organs most damaged by long-term Type 2 diabetes.

The FLOW trial (Novo Nordisk) demonstrated in 2024 that semaglutide significantly reduced kidney disease progression in Type 2 diabetes patients with chronic kidney disease — a landmark finding now reshaping treatment guidelines. Follow-up mechanistic studies are enrolling in 2025 to understand exactly how GLP-1 agonists protect kidney function.

AstraZeneca's DAPA-CKD successor studies continue enrolling patients, examining whether dapagliflozin (Farxiga) provides kidney protection beyond what's currently approved. SGLT2 inhibitors remain one of the hottest areas of diabetes cardiovascular research, with multiple trials examining their role in heart failure prevention among Type 2 diabetes patients.

Novel Targets: Inflammation, Beta Cell Preservation, and Beyond

Several 2025 trials are exploring genuinely novel mechanisms. Verapamil's potential to preserve beta cell function in recently diagnosed Type 2 diabetes continues in follow-up studies from the University of Alabama's VERAPAMIL-T2D program. Separately, anti-inflammatory approaches targeting IL-1 receptor antagonism are in mid-stage trials, based on evidence that chronic low-grade inflammation drives insulin resistance.

Zealand Pharma and several biotech companies are enrolling patients for trials of novel glucagon receptor antagonists — a mechanism that reduces liver glucose production through a different pathway than existing drugs.

Current Status (2025)

The most mature trials — retatrutide Phase 3 and CagriSema Phase 3 — could yield FDA submission-ready data by 2026-2027 if results are strong. Oral insulin remains 3-5 years from potential approval at best. Cardiorenal trials are producing data that is already changing clinical guidelines now, meaning patients with Type 2 diabetes and kidney or heart disease may benefit from updated prescribing recommendations in 2025 even without waiting for new approvals.

Patients and clinicians managing current therapy — including monitoring supplies available through resources like mdsdiabetes.com — should stay current with evolving guidelines as trial data emerges throughout 2025.

What This Means for Patients

If you have Type 2 diabetes, you may qualify for trials that provide cutting-edge treatments at no cost. Key steps: visit ClinicalTrials.gov and search "Type 2 diabetes" filtered by "Recruiting" status and your location. Discuss any trial with your endocrinologist before enrolling — trials have strict eligibility criteria and some require stopping current medications. Participation is voluntary and you can withdraw at any time.

Even if you don't join a trial, staying informed means you'll be ready to discuss newly approved treatments with your doctor as soon as they become available.

Timeline: When Could These Reach Patients?

• 2025-2026: Updated cardiorenal guidelines based on existing trial data already impacting prescribing
• 2026-2027: Potential FDA submissions for retatrutide and CagriSema if Phase 3 data is strong
• 2027-2028: Possible oral insulin approvals if current Phase 3 programs succeed
• 2028+: Novel anti-inflammatory and beta cell preservation therapies, pending further trial results